Hospital
Crossett Health Foundation
Crossett Health Foundation was paid $3.38M by Medicaid between Jan 2018 and Dec 2024, across 121 billing codes. Its largest line is 96365, Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour — 17% of everything it billed.
33Billing provider infoCROSSETT HEALTH FOUNDATION
CROSSETT, AR 71635
CROSSETT, AR 71635
33aNPI1952308215assigned 07/01/2005
33bProvider typeCritical Access Hospital
28Total paid$3.38M
24GClaims155,755
24DCodes billed121
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Arkansas
Rank by total paid#2 of 34
Median peer was paid$773K
This provider vs. median4.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 19,631 | $337K | |
| 2019 | 22,461 | $477K | |
| 2020 | 20,569 | $413K | |
| 2021 | 25,112 | $566K | |
| 2022 | 26,202 | $624K | |
| 2023 | 23,597 | $538K | |
| 2024incomplete | 18,183 | $425K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 17% | 6,181 | 3,826 | $574K |
| 80053 | Comprehensive metabolic panel | 8.2% | 15,220 | 12,487 | $276K |
| 87631 | 5.4% | 1,873 | 1,675 | $183K | |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 5.4% | 3,790 | 2,845 | $181K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 4.7% | 19,570 | 15,858 | $159K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.4% | 4,529 | 1,155 | $147K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.8% | 1,124 | 972 | $129K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 3.4% | 2,598 | 2,327 | $114K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.6% | 1,166 | 710 | $89K |
| 84443 | Thyroid stimulating hormone (TSH) | 2.4% | 5,475 | 4,845 | $82K |
| 83880 | 2.2% | 2,277 | 1,978 | $74K | |
| 80050 | General health panel | 2.0% | 1,448 | 1,432 | $69K |
109 more codes
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.0% | 333 | $68K |
| 80061 | Lipid panel | 1.9% | 3,580 | $65K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.9% | 4,986 | $65K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.6% | 242 | $55K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.6% | 475 | $53K |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.5% | 3,510 | $49K |
| 80305 | 1.4% | 2,616 | $48K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.4% | 3,185 | $48K |
| 71046 | Radiologic examination, chest; 2 views | 1.3% | 1,841 | $45K |
| 59025 | Fetal non-stress test | 1.3% | 230 | $45K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.2% | 1,305 | $42K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.2% | 665 | $40K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.1% | 3,925 | $36K |
| 87070 | <1% | 2,184 | $34K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 194 | $30K |
| 84484 | <1% | 2,612 | $30K | |
| 71045 | Radiologic examination, chest; single view | <1% | 2,709 | $28K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,488 | $28K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 1,347 | $25K |
| 36415 | Collection of venous blood by venipuncture | <1% | 6,888 | $25K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 3,664 | $25K |
| 99284 | Emergency room visit (serious) | <1% | 802 | $23K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 477 | $23K |
| 83735 | <1% | 2,826 | $21K | |
| 87400 | <1% | 1,875 | $17K | |
| 87186 | <1% | 2,007 | $17K | |
| 82550 | <1% | 1,906 | $15K | |
| 81001 | <1% | 4,278 | $15K | |
| 82553 | <1% | 1,318 | $14K | |
| 87088 | <1% | 1,219 | $14K | |
| 97161 | <1% | 250 | $14K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,047 | $13K |
| 87581 | <1% | 242 | $12K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 201 | $12K |
| 83690 | <1% | 1,157 | $12K | |
| 83874 | <1% | 968 | $11K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 92 | $11K |
| 82728 | <1% | 699 | $10K | |
| 81025 | <1% | 1,178 | $10K | |
| 85610 | <1% | 2,316 | $9K | |
| 85730 | <1% | 1,457 | $9K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 35 | $7K |
| 82150 | <1% | 818 | $7K | |
| 84439 | <1% | 467 | $6K | |
| 86901 | <1% | 446 | $6K | |
| 83540 | <1% | 867 | $6K | |
| 74018 | <1% | 200 | $6K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,471 | $5K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 62 | $4K |
| 81003 | <1% | 1,835 | $4K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 892 | $4K |
| 87077 | <1% | 223 | $4K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 13 | $4K |
| A9270 | Non-covered item or service | <1% | 3,290 | $4K |
| 83605 | <1% | 303 | $3K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 50 | $3K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 45 | $3K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 12 | $3K |
| 97597 | <1% | 38 | $3K | |
| 80164 | <1% | 85 | $3K | |
| 73610 | <1% | 132 | $3K | |
| 83550 | <1% | 257 | $3K | |
| 73630 | <1% | 97 | $3K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 56 | $3K |
| 86140 | <1% | 381 | $2K | |
| 85651 | <1% | 563 | $2K | |
| 97001 | <1% | 53 | $2K | |
| 71020 | <1% | 131 | $2K | |
| 82607 | <1% | 143 | $2K | |
| 0001A | <1% | 76 | $2K | |
| 86850 | <1% | 296 | $2K | |
| 82565 | <1% | 97 | $2K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 118 | $2K |
| 84146 | <1% | 33 | $2K | |
| 84702 | <1% | 171 | $2K | |
| 86900 | <1% | 400 | $2K | |
| 73030 | <1% | 53 | $2K | |
| 87420 | <1% | 137 | $2K | |
| 87040 | <1% | 110 | $1K | |
| 73130 | <1% | 48 | $1K | |
| 73110 | <1% | 27 | $1K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 71 | $1K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 13 | $1K |
| 71010 | <1% | 142 | $934.51 | |
| 77066 | Tomosynthesis, mammo | <1% | 13 | $900.40 |
| 0002A | <1% | 43 | $870.52 | |
| 86592 | <1% | 243 | $840.59 | |
| 73564 | <1% | 26 | $820.48 | |
| 73562 | <1% | 25 | $818.76 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 61 | $676.67 |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 12 | $600.00 |
| 80320 | <1% | 47 | $531.66 | |
| 80329 | <1% | 48 | $501.52 | |
| 84550 | <1% | 80 | $492.46 | |
| 83615 | <1% | 61 | $417.81 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 83 | $394.68 |
| 87075 | <1% | 13 | $360.39 | |
| 83020 | <1% | 14 | $202.29 | |
| 82948 | <1% | 18 | $169.72 | |
| 82248 | <1% | 15 | $86.04 | |
| 82570 | <1% | 13 | $83.63 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 127 | $73.58 |
| 82043 | <1% | 13 | $57.89 | |
| 87340 | <1% | 27 | $44.25 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 174 | $16.30 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 69 | $7.29 |
| 91300 | <1% | 41 | $0.38 | |
| 86762 | 0% | 13 | $0.00 | |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 174 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGILMORE, PHILLIP (CEO)
| Provider | Location | Paid |
|---|---|---|
| Crossett Health Foundation | Hamburg, AR | $431K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.